Group One Trading, L.P. Tg Therapeutics, Inc. Transaction History

Group One Trading, L.P.

  • $3.01 Billion
  • Q2 2024

A detailed history of Group One Trading, L.P. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 618,654 shares of TGTX stock, worth $16.8 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
618,654
Previous 608,282 1.71%
Holding current value
$16.8 Million
Previous $9.25 Million 18.96%
% of portfolio
0.37%
Previous 0.34%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$13.32 - $19.19 $138,155 - $199,038
10,372 Added 1.71%
618,654 $11 Million
Q1 2024

May 10, 2024
SELL
$13.02 - $21.3 $5.06 Million - $8.28 Million
-388,560 Reduced 38.98%
608,282 $9.25 Million
Q4 2023

Feb 14, 2024
BUY
$6.68 - $18.81 $2.27 Million - $6.39 Million
339,803 Added 51.72%
996,842 $17 Million
Q3 2023

Nov 09, 2023
BUY
$8.36 - $26.5 $3.17 Million - $10 Million
378,731 Added 136.08%
657,039 $5.49 Million
Q2 2023

Aug 09, 2023
SELL
$15.48 - $35.0 $369,677 - $835,835
-23,881 Reduced 7.9%
278,308 $6.91 Million
Q1 2023

May 12, 2023
SELL
$10.23 - $19.34 $5.37 Million - $10.1 Million
-524,460 Reduced 63.44%
302,189 $4.54 Million
Q4 2022

Feb 09, 2023
SELL
$5.01 - $11.83 $1.69 Million - $3.98 Million
-336,402 Reduced 28.92%
826,649 $9.78 Million
Q3 2022

Nov 09, 2022
BUY
$4.57 - $8.4 $304,736 - $560,128
66,682 Added 6.08%
1,163,051 $6.89 Million
Q2 2022

Aug 11, 2022
SELL
$3.74 - $10.66 $2.7 Million - $7.71 Million
-723,175 Reduced 39.74%
1,096,369 $4.66 Million
Q1 2022

May 12, 2022
SELL
$7.81 - $20.45 $464,960 - $1.22 Million
-59,534 Reduced 3.17%
1,819,544 $17.3 Million
Q4 2021

Feb 11, 2022
BUY
$15.2 - $35.51 $2.83 Million - $6.62 Million
186,407 Added 11.01%
1,879,078 $35.7 Million
Q3 2021

Nov 12, 2021
BUY
$21.78 - $40.45 $17.3 Million - $32.2 Million
794,981 Added 88.56%
1,692,671 $56.3 Million
Q2 2021

Aug 10, 2021
BUY
$32.5 - $48.96 $13.2 Million - $19.9 Million
406,434 Added 82.73%
897,690 $34.8 Million
Q1 2021

May 12, 2021
BUY
$41.61 - $54.3 $13.5 Million - $17.7 Million
325,630 Added 196.61%
491,256 $23.7 Million
Q4 2020

Feb 10, 2021
SELL
$25.27 - $54.9 $3.15 Million - $6.84 Million
-124,676 Reduced 42.95%
165,626 $8.62 Million
Q3 2020

Nov 12, 2020
BUY
$18.49 - $27.24 $3 Million - $4.42 Million
162,210 Added 126.64%
290,302 $7.77 Million
Q2 2020

Aug 13, 2020
BUY
$8.9 - $21.84 $580,965 - $1.43 Million
65,277 Added 103.92%
128,092 $2.5 Million
Q1 2020

May 13, 2020
SELL
$7.14 - $15.99 $204,346 - $457,633
-28,620 Reduced 31.3%
62,815 $618,000
Q4 2019

Feb 10, 2020
BUY
$5.1 - $11.2 $217,989 - $478,721
42,743 Added 87.78%
91,435 $1.02 Million
Q3 2019

Nov 12, 2019
BUY
$5.38 - $8.99 $261,962 - $437,741
48,692 New
48,692 $273,000
Q2 2019

Aug 09, 2019
SELL
$6.27 - $8.65 $688,609 - $949,994
-109,826 Closed
0 $0
Q1 2019

May 13, 2019
SELL
$4.02 - $8.04 $145,556 - $291,112
-36,208 Reduced 24.79%
109,826 $883,000
Q4 2018

Feb 06, 2019
BUY
$3.44 - $5.76 $1,338 - $2,240
389 Added 0.27%
146,034 $599,000
Q3 2018

Nov 08, 2018
SELL
$5.15 - $14.0 $269,880 - $733,656
-52,404 Reduced 26.46%
145,645 $816,000
Q2 2018

Aug 14, 2018
BUY
$12.5 - $15.0 $207,150 - $248,580
16,572 Added 9.13%
198,049 $2.6 Million
Q1 2018

May 11, 2018
BUY
$8.7 - $16.8 $418,330 - $807,811
48,084 Added 36.05%
181,477 $2.58 Million
Q4 2017

Feb 09, 2018
BUY
$7.35 - $12.3 $284,525 - $476,145
38,711 Added 40.89%
133,393 $1.09 Million
Q3 2017

Nov 15, 2017
SELL
$10.0 - $12.7 $292,810 - $371,868
-29,281 Reduced 23.62%
94,682 $1.12 Million
Q2 2017

Aug 14, 2017
BUY
N/A
123,963
123,963 $1.25 Million

Others Institutions Holding TGTX

# of Institutions
307
Shares Held
92.8M
Call Options Held
1.9M
Put Options Held
1.45M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $3.95B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email